Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 13/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421201 | 0.89 | GRIN2B (0.47) | GRIN2BGRIN1CYP2C9KCNH2L3MBTL3 | |
| SCHEMBL1421105 | 0.89 | GRIN2B (0.50) | GRIN2BGRIN1CYP2C9KCNH2L3MBTL3 | |
| SCHEMBL1420727 | 0.88 | GRIN2B (0.48) | GRIN2BGRIN1CYP2C9KCNH2L3MBTL3 | |
| SCHEMBL1420729 | 0.86 | L3MBTL1 (0.46) | GRIN2BL3MBTL3L3MBTL1TDP1 | |
| SCHEMBL1083719 | 0.85 | CCR5 (0.51) | L3MBTL3L3MBTL1IRAK4TDP1 | |
| SCHEMBL1421243 | 0.85 | L3MBTL1 (0.44) | GRIN2BGRIN1L3MBTL3L3MBTL1TDP1 | |
| SCHEMBL1420734 | 0.85 | GRIN2B (0.47) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL1420737 | 0.85 | GRIN2B (0.47) | GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL4411269 | 0.84 | L3MBTL3 (0.43) | GRIN2BGRIN1L3MBTL3L3MBTL1 | |
| SCHEMBL1083716 | 0.84 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | claimed |
| JP-2011524400-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2297137-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | claimed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | claimed |
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2297137-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | CCR3, CCR2, CCR1 | GRIN2B 491/4885GRIN1 634/4885CYP2C9 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.